33 studies found for:    " April 22, 2009":" May 22, 2009"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
Rank Status Study
21 Unknown  Cognitive and Psychosocial Benefits of MISC Training for Ugandan Children
Conditions: HIV;   HIV Infections
Intervention: Behavioral: MISC training for primary caregivers
22 Completed Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
Conditions: HIV;   Hyperlipidemia;   Hypertriglyceridemia;   HIV Infections
Intervention: Drug: raltegravir
23 Active, not recruiting Coronary Artery Disease and Its Association With Liver Steatosis Among HIV-Infected Persons
Conditions: HIV Infections;   Coronary Artery Disease;   Non-Alcoholic Fatty Liver Disease
Intervention:
24 Completed
Has Results
A Phase I Multiple Dose Pharmacokinetic Study of Nevirapine Extended Release (XR) in HIV-1 Infected Children.
Condition: HIV Infections
Interventions: Drug: Nevirapine Immediate Release (IR);   Drug: Nevirapine Extended Release (XR)
25 Unknown  Trends in Risk Factors for Mother-to-Child Transmission of Hepatitis C Among a Southern European Population
Conditions: Hepatitis C Virus;   HIV Infections;   Pregnancy
Intervention:
26 Terminated PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.
Condition: HIV Infections
Intervention: Drug: TMC589337, TMC589354, TMC310911, placebo
27 Unknown  Safety and Efficacy of GS-9350-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Condition: HIV-1 Infection
Interventions: Drug: 150 mg tablet GS- 9350;   Drug: ritonavir 100 mg capsule;   Drug: atazanavir 300 mg capsule;   Drug: emtricitabine/tenofovir DF 200/300 mg tablet;   Drug: ritonavir placebo;   Drug: GS-9350 placebo
28 Withdrawn Trial of TDF/FTC + Raltegravir Versus TDF/FTC + Efavirenz in HIV-1-Infected Women
Condition: HIV-1 Infections
Interventions: Drug: TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily;   Drug: TDF/FTC + Efavirenz (Atripla) Once-Daily
29 Unknown  Examining Hair to Determine Tenofovir Exposure
Condition: HIV
Intervention: Drug: Tenofovir Disoproxil Fumarate
30 Completed A Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions
Conditions: Postherpetic Neuralgia;   Diabetic Neuropathy;   Complex Regional Pain Syndrome;   Carpal Tunnel Syndrome;   HIV Neuropathy;   Idiopathic Sensory Neuropathy;   Peripheral Neuropathy
Interventions: Drug: Placebo Capsules + Placebo Patch;   Drug: Placebo capsules + Lidoderm®;   Drug: Gabapentin + Placebo;   Drug: Gabapentin + Lidoderm®;   Drug: Gabapentin 300 mg capsules 1800 mg/day + placebo patch;   Drug: Gabapentin 1800 mg/day + Lidoderm patch
31 Completed A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)
Condition: HIV-1 Infection
Interventions: Biological: V520;   Biological: Comparator: ALVAC-HIV vaccine
32 Completed CyberSenga: Internet-based HIV Prevention in Uganda
Conditions: Sexual Abstinence;   Condom Use
Intervention: Behavioral: CybereSenga
33 Withdrawn Collecting and Storing Blood Samples From Patients With Cancer
Conditions: Brain and Central Nervous System Tumors;   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-33) Next Page
Indicates status has not been verified in more than two years